Compelling in vivo and in vitro data published in peer-reviewed Journal for ImmunoTherapy of Cancer (JITC)Secarna's LNAplus-based ASOs effectively stimulate TLR9 signaling, an important innate immune pathway
DGAP-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Study First subject dosed in Lipigon’s phase I clinical study with antisense oligonucleotide candidate derived from Secarna Pharmaceutical’s LNAplus™ technology platform 31.05.2022 / 14:00 The issuer is solely responsible for th.
DGAP-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Miscellaneous 12.04.2022 / 14:00 The issuer is solely responsible for the content of this announcement. Secarna Pharmaceuticals strategic partner Evotec achieves programme designation in neuroscience collaboration with Bristo.
DGAP-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Expansion Secarna Pharmaceuticals partner Denali Therapeutics exercises option for LNAplusTM antisense oligonucleotide development program in neurodegeneration 22.02.2022 / 14:00 The issuer is solely responsible for the content.
DGAP-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Agreement Secarna Pharmaceuticals and Denali Therapeutics expand strategic partnership for the discovery and development of novel ASO therapeutics in the field of CNS diseases 26.10.2021 / 15:00 The issuer is solely responsible .